ZLDPF Zealand Pharma A/S

New Employee Elected Directors to the Board of Zealand Pharma A/S

New Employee Elected Directors to the Board of Zealand Pharma A/S

Company announcement – No. 14 / 2024

New Employee Elected Directors to the Board of Zealand Pharma A/S

Copenhagen, Denmark, March 13, 2024 Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78). The employees of Zealand Pharma A/S have elected the following employee representatives and alternates for the Company’s Board of Directors:

Employee representatives:

  • Frederik Beck (re-elected)
  • Anneline Nansen (re-elected)
  • Ludovic Otterbein (newly elected)
  • Adam Nygaard (newly elected)

As alternates for the employee-elected board members, the following were elected:

  • Tanja Erichsen
  • Katja Hansen
  • Lars Pedersen
  • Cecilie Kold

The new employee-elected board members will join the Board of Directors following the annual general meeting of Zealand Pharma A/S on 20 March 2024. At the same time the current board members Jens Peter Stenvang, who did not run for election, and Louise Gjelstrup, who did not run for election, will step down from their positions on the Board.

About employee-elected board members

According to the Danish Companies Act, the employees of Zealand Pharma A/S are entitled to be represented by half of the total shareholder-elected Board members. Employee-elected board members serve for a statutory four-year term and have the same rights, duties and responsibilities as shareholder-elected board members.

# # #

About Zealand Pharma A/S

Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. The company has development partnerships with a number of blue-chip pharma companies as well as commercial partnerships for its marketed products.

Zealand was founded in 1998 and is headquartered in Copenhagen, Denmark, with a presence in the U.S. For more information about Zealand’s business and activities, please visit .

Contact:

Anna Krassowska, PhD

Vice President, Investor Relations & Corporate Communications

Zealand Pharma

Email:


EN
13/03/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Zealand Pharma A/S

 PRESS RELEASE

Zealand Pharma to participate in upcoming investor conferences in Marc...

Zealand Pharma to participate in upcoming investor conferences in March 2026 Press release – No. 5 / 2026 Zealand Pharma to participate in upcoming investor conferences in March 2026 Copenhagen, Denmark, March 9, 2026 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today announced that the company will participate in the following investor conferences in March 2026. 2026 Jefferies Biotech on the Beach Summit, March 9-11 in Miami Adam Steensberg, President and Chief Executive Officer, will host investor meetings...

BC-bc user ... (+8)
  • BC-bc user
  • Guy Sips
  • Hilde Van Boxstael
  • Jacob Mekhael
  • Livio Luyten
  • Lynn Hautekeete
  • Michiel Declercq
  • Wim Lewi

Morning Notes : ATEB BB, COMB BB, BPOST BB, ELI BB, GLPG NA, JEN BB, H...

: ATEB BB, COMB BB, BPOST BB, ELI BB, GLPG NA, JEN BB, HYSG BB, ZEAL DC, ECMPA NA

Jacob Mekhael
  • Jacob Mekhael

Zealand Pharma Petrelintide shows modest weight loss but excellent tol...

Zealand reported mixed results from the phase 2 (ZUPREME-1) trial of petrelintide in overweight/obesity, showing a modest 10.7% weight loss at 42 weeks, while demonstrating excellent tolerability. We think this outcome makes first line positioning difficult, and view petrelintide as better suited for weight loss maintenance (subject to positive data in that setting). We adjust our peak sales estimate to $ 7b (from $ 22b), which brings down our TP to DKK 500 (from DKK 960). Given the lower upside...

 PRESS RELEASE

Zealand Pharma announces positive Phase 2 results for petrelintide, an...

Zealand Pharma announces positive Phase 2 results for petrelintide, an amylin analog with potential to redefine the weight management experience for people living with overweight and obesity Company announcement – No. 3 / 2026 Zealand Pharma announces positive Phase 2 results for petrelintide, an amylin analog with potential to redefine the weight management experience for people living with overweight and obesity Petrelintide achieved up to 10.7% mean body weight reduction at week 42 (versus 1.7% with placebo) and demonstrated placebo-like tolerabilityAt the maximally effective dose, the...

 PRESS RELEASE

Zealand Pharma convenes its Annual General Meeting 2026

Zealand Pharma convenes its Annual General Meeting 2026 Company announcement – No. 2 / 2026 Zealand Pharma convenes its Annual General Meeting 2026 Copenhagen, Denmark, February 19, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, hereby convenes its Annual General Meeting 2026. The Board of Directors of Zealand Pharma A/S hereby convenes the Annual General Meeting of the Company to be held on: Thursday, 26 March 2026 at 03:00 PM (CET) / 9:00 (ET) The Annual General Meet...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch